MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, announced its underwritten public offering, raising $30.0 million in gross proceeds, before underwriting discounts and offering expenses.
The offering consisted of 20,000,000 shares of common stock priced at $1.50 per share. In addition, the Company granted the underwriters a 45-day option to purchase up to an additional 3,000,000 shares of common stock to cover over-allotments, if any.
Net proceeds from the offering are expected to be used to support the Company’s clinical trials, as well as for working capital and general corporate purposes.
Lucosky Brookman LLP served as legal counsel to the placement agent in connection with the offering. Konik Capital Partners, LLC, a division of T.R. Winston & Company, acted as sole book-running manager for the offering.
